Description
Indication & Scope
XianYiDa® Ecnoglutide Injection helps with subcutaneous glycemic control to lower fasting and postprandial blood glucose in adult patients with type 2 diabetes mellitus.
- Mechanism: Ultra-long acting glucagon-like peptide-1 (GLP-1) receptor agonist with extended serum half-life. It activates pancreatic GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying and reduce central nervous system appetite signaling; delivers sustained blood glucose reduction and mild body weight loss with once-weekly administration.
- Drug class: Long-acting weekly GLP-1 receptor agonist / Injectable hypoglycemic peptide biologic drug.
- Clinical use: Single-agent glycemic management for newly diagnosed type 2 diabetes adults; combination therapy with oral metformin for enhanced glucose and weight control in patients with suboptimal oral monotherapy response.
- Related Product: The same active ingredient is also marketed in China as Xianweiying® for chronic weight management in adults with overweight or obesity. Although both products contain Mazdutide, they are approved for different therapeutic indications.
- → View XianWeiYing® Ecnoglutide Injection (Weight Management)
| Generic Name | Ecnoglutide Injection |
| Brand Name | XianYiDa |
| Ingredient | Ecnoglutide |
| Dosage Form | Injection |
| Package | 2.0mg/ml, 1.2ml*1 syringe/box;
4.0mg/ml, 1.2ml*1 syringe/box |
| Conditions Treated | Type 2 diabetes mellitus in adult patients requiring sustained weekly blood glucose regulation |
| Taboos | Personal or family medical history of medullary thyroid carcinoma (MTC); multiple endocrine neoplasia syndrome type 2 (MEN2); severe hypersensitivity to GLP-1 peptide or pen formulation excipients; pregnant and breastfeeding women |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Unopened unused injection pens refrigerated at 2°C–8°C, avoid freezing; after first needle puncture for administration, store pen below 25°C away from sunlight for maximum 4 weeks |
| Manufacturer | Amphastar Nanjing Pharmaceuticals Inc. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20260013; S20260014 |
| Approval Date | Mar 3, 2026 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Initial titration starting dose: 0.2 mg once weekly subcutaneously; escalate incrementally to maintenance therapeutic doses of 0.6 mg or 1.0 mg weekly based on individual HbA1c and weight response.
Time: Single subcutaneous injection administered once every 7 days, flexible timing independent of daily meal schedules.
Instructions for use: Deliver subcutaneous injection into abdomen, thigh or upper arm adipose tissue; rotate injection sites weekly to prevent local inflammatory reactions; initiate low starting dose to minimize gastrointestinal adverse effects; screen thyroid cancer family history prior to treatment initiation.
Interaction: Concurrent insulin or sulfonylurea oral hypoglycemics significantly increase severe hypoglycemia risk; oral nutrient supplements containing calcium/magnesium delay gastrointestinal peptide absorption and reduce peak therapeutic efficacy.
Side effects:
1. Common mild transient adverse reactions: nausea, vomiting, diarrhea, injection site erythema, mild appetite suppression, fatigue.
2. Rare severe risks: acute gallstone pancreatitis, severe symptomatic hypoglycemia, thyroid C-cell tumor proliferative risk, anaphylactic hypersensitivity.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What endogenous gastrointestinal hormone receptor does Ecnoglutide Injection activate to mediate its glucose-lowering and weight-loss therapeutic effects in type 2 diabetes?
It acts as an agonist for the glucagon-like peptide-1 (GLP-1) receptor expressed on pancreatic, gastric and central nervous system tissues.
What two patient populations carry absolute contraindications to Ecnoglutide Injection due to class-wide GLP-1 thyroid safety warnings?
Patients with personal/familial medullary thyroid carcinoma history and individuals diagnosed with multiple endocrine neoplasia type 2 syndrome.
What is the standard administration frequency of Ecnoglutide Injection pen for chronic type 2 diabetes management?
Subcutaneous injection once every seven days (once-weekly maintenance therapy after dose titration).
What common dose-limiting adverse reaction requires slow incremental weekly dose escalation during Ecnoglutide Injection treatment initiation?
Transient gastrointestinal side effects including nausea, vomiting and delayed gastric emptying.
XianYiDa® | Ecnoglutide Injection | Type 2 Diabetes | DengYueRX
INN: Ecnoglutide Injection
Indications: Type 2 diabetes
Dosage Form: Injection
Strength: 2.0mg/ml, 1.2ml/syringe; 4.0mg/ml, 1.2ml/syringe
Related Product: XianWeiYing® Ecnoglutide Injection
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
